## H1 2023-2024 results

Analyst & Press conference

23 November 2023









HEALTHCARE



LIFE SCIENCES



SMART INDUSTRIES



SUSTAINABLE CITIES















# Strong results in H1 2023-24 confirm value creation strategy through growth

- Double-digit topline and profitability growth at our portfolio companies
- Realised value creation through exits
- Portfolio result of € 203m (non-annualized portfolio return of 13.3%)
- Continued portfolio growth to more than € 1.6bn
- Net result of more than € 150mio drives strong increase in NAV/share to € 51,3
- Solid liquidity position

### Key figures H1 2023-2024

>€ 1.6bn

17% Sales growth
13% EBITDA growth

In portfolio companies (H1-on-H1)

€ 158mio

Exit proceeds (realized money multiple of 1.9x\*)

€ 203mio

portfolio result

€ 51.3/share

NAV as at 30/9/23

13.3%

portfolio return

€ 85mio

portfolio invested

in **59** companies

Investments in 3 new companies and intensive buy & build activity

€ 192mio

Available liquidity



<sup>\*</sup> Money multiple includes exit Groupe Claire, cash proceeds received after H1 closure end October 2023



### Our companies grow in an economy "in dubio"...

- Sometimes overwhelmed by fast developing geopolitical tensions
- The economic evolution is unevenly distributed between sectors and regions.
- Some sectors are doing well with a remarkable margin recovery after the cost explosions.
- Others are suffering from a weakening demand and are still impacted by the reminiscences of the energy crisis and inflationary pressure:
  - Lower investment levels in the <u>capital intensive/heavy industries</u>
  - <u>Construction</u>: decrease in activity mainly triggered by a real estate financing crisis, expected to recover; combined with a Schumpeterian creative destruction towards carbon neutral offices/housing
  - <u>Chemistry</u>: current situation differs case-by-case, with energy costs and circularity as key decisive elements
  - <u>Consumption</u>: from a covid "in and round" the house consumption to a post-covid quest for "experience" to a current more normalized situation




#### ... stuck between Tesla and BYD

- Most of our portfolio companies are active in an "open" economy and can thrive in free
  markets; However, we are currently confronted with deglobalisition, a series of national
  protectionist measures and increasing state support. Some are fast adapters...
- Europe urgently needs to take position vs. US, Asia,... in order to safeguard a future for the European industry and economy in a world that increasingly is less "Westerncentric". We need to get our act together: a visionary **European industrial policy**, and this at the level of the regions, countries and in Europe as a whole.
- Available strengths: innovation and automation, well educated population, localization and capacity to create alliances and clusters (e.g. with logistics platforms)
- Some structural European disadvantages have to be tackled: absence of own natural and energy resources, tight budgetary restrictions, limited scale and regional differences
- We are evolving from an era with many changes to... a changing era: "From opportunity to necessity"




### H1 2023-24 Portfolio result endorses return target



- Total portfolio result in H1 2023-24 of € 202.8mio
  - € 69.8mio realised result, ao. capital gain on exits
  - € 115.7mio unrealised result, mainly driven by solid performance growth of our portfolio companies
  - € 17.4mio interest income
- Total portfolio return of 13.3% for the first 6 months (non-annualised), well within our target to reach annual portfolio return target of 15%


### Strong topline and profitability growth across all platforms







# Unrealised result of €115.7mio Portfolio performance growth is the key value driver




- Solid growth performance of the portfolio is the main contributor to the H1 unrealised result. With overall double-digit turnover and profitability growth, our portfolio companies clearly outperformed the total economy.
- The rise in Net Financial Debt is primarily (>70%) linked with buy-and-build.
- The weighted average EBITDA multiple amounts to 8.7x by end September 2023 (after stable average calibration effect or discount of -21%). The lower multiple (from 8.8x end March 23) is in line with the evolution of the financial markets over the same period

### Unrealised result H1 2023-24 per platform

#### Consumer


- Most companies show improved performance
- Some companies still face increased costs and are impacted by lagging effect of price increases





#### Life Sciences

- Listed portfolio negatively impacted by volatility in capital markets
- Majority on track and funded to reach next milestones




### Unrealised result H1 2023-24 per platform

#### **Smart Industries** Strong performance confirms relaunch after year with strong margin pressure - Able to expand EBITDA margin and keep working capital requirements under control NFD increase mainly driven by buy and build H1 unrealised result of € 39,6mio H1 drivers of valuation: 90,3 ■ EBITDA or Sales -22,3 ■ Multiples ■ Net financial debt -26,6 ■ Write downs -2,1





### Stable limited average leverage exposure in our portfolio



- The average leverage (NSFD/EBITDA) of our portfolio is 1.9x (in line with FY 2022-23 1.8x)
- Only 16% of our portfolio has a current Net Financial Debt/EBITDA ratio in excess of 4x (coming from 24% as at end March 2023)
- Almost half of our portfolio has none to a limited leverage below 2x

### Outlook for our companies


 The FY 2023 portfolio figures are estimated to confirm a solid top-line and profitability growth.

#### • For FY 2024:

- It remains to be seen whether decreasing input prices will result in a structurally lower inflation
- It is not yet clear how a possible slowdown in demand in certain sectors might impact order books and growth
- Interest rates are expected to stabilize (inflation evolution will decide). Impact of interest rates currently manageable for most of our companies (also given the average limited use of debt financing)




# Continued portfolio growth to more than € 1.6bn Focus on value creation



- Over the last years our portfolio growth has accelerated to record levels
- 8% portfolio growth in H1
   2023-24 to more than € 1.6bn
   (incl. Groupe Claire)
- 59 portfolio companies well distributed across 5 platforms and 4 countries
- More than 2/3 of the platform portfolio is invested since 2018, resulting in a large and young portfolio with attractive value potential



# H1 2023-24 Investments at € 85mio 3 new companies and strategic add-ons



 € 43.1mio invested in 3 new portfolio companies:

**ERS** 

SI; G; May 2023

Global leader in thermal management solutions for semiconductor manufacturing



SI; NL; April 2023

Developer and manufacturer of highprecision and high-tech parts and (sub)sytems manufacturing



LS; UK; May 2023

Developing the next generation of complement medicines


 € 41.4mio invested in existing portfolio a.o. for bolt-on acquisitions (see next slide)



## Value creation through buy-and-build as a material part of our core business and value creation

#### 14 bolt-on acquisitions are realised in our portfolio in H1 2023-24

- Buy & build remains an integrated part of our value creation approach
- Combination of auto-financing capacity and Gimv add-on investments





# H1 2023-24 Exit proceeds at € 158mio (excl. Groupe Claire\*) 4 full exits realised in difficult market environment

• 4 full exits realised in H1 2023-24:









with a combined realised money multiple of 1.9x and an IRR of 16.4%

(\*) Final close exit Groupe Claire end of October 2023







## Further improving our Sustainalytics ESG risk rating in an increasing ESG risk environment - **top-quartile position in our industry**

Gimy NV

High Level Score Changes				Multi-Sector Holdings		ngs	Belgium	BRU:GIMB
	Previous score Dec 22	Current score Nov 23	Score Change					
				Current score	10.6			
Overall ESG Risk Score	<b>11.0</b> Low Risk	<b>10.6</b> Low Risk	-0.4	NEGL 0 - 10	LOW 10 - 20	MED 20 - 30	HIGH 30 - 40	SEVERE 40+
				Previous score	▲ 11.0			
			С	urrent score 24.1				
Exposure Score  Based on external factors	23.9	24.1	+0.2	Low	MED	HIGH		
	Low	Low	Pr	0 - 35 ▲ evious score 23.9	35 - 55 <b>9</b>	55+		
				Current score 57	'.1			
Management Score	55.1	57.1	+2.0	STRONG	AVERAGE	WEAK		
	Strong	Strong	_	100 - 50	50 - 25	25 - 0		
			P	revious score 55	5.1			




High Layol Score Changes



## NAV per share grows from € 45,6 to € 51,3


(in € mio)



(\*) Net of € 2,6 dividend on FY 2022-23



# Growth at portfolio companies as the key source of value creation (data based on exits as of 2014)







## Five largest investments make up almost 30% of portfolio value (based on NAV of 30 September 2023) > rank 1 to 5

Company	Activity	Platform	Location	Entry
C cegeka	Independent European ICT service provider	37	Belgium	2017
claire	Equipment and solutions for the efficiency of the drinking water network	<b>(1)</b>	France	2018
MEDI - MARKT gut beraten – besser teben	Service provider in incontinence care @home		Germany	2018
PICOT	Production of gates and fencing & provider of fencing solutions	37	France	2022
by spineart	Medical device company active in spine surgery		Switzerland	2016

Subtotal NAV 5 largest investments (in € mio)





## Twenty largest investments (ctd) > rank 6 to 10

Company	Activity	Platform	Location	Entry
televic communication that matters	Supplier of high-tech/high-quality communication systems	37	Belgium	2020
<b>s</b> ofatutor	Online learning platform	ظ <b>﴾</b>	Germany	2021
<b>⊘</b> rehaneo	Ambulatory rehabilitation provider		Germany	2020
VARIASS	Developer and manufacturer of electronic and mechatronic products and systems	3	The Netherlands	2022
ALRO GROUP WE COLOUR YOUR MOBILITY	Industrial coating of trucks and car parts	3	Belgium	2019

Subtotal NAV 10 largest investments (in € mio)





## Twenty largest investments (ctd) > rank 11 to 15

Company	Activity	Platform	Location	Entry
UNITED DUTCH BREWERIES	Independent beer group	ظ}	The Netherlands	2015
KÖBERL Group	Facility management and technical building services	<b>(1)</b>	Germany	2019
BIO CONNECTION  RATURG MEET IN BOTHMANGGITCH, SONGO-MENT A MINARCHING	A CDMO for injectable (bio)pharmaceutical products		The Netherlands	2022
VERKLEY KABELS A LEIDINGEN	Specialist contractor in cable and pipeline networks for energy and water	<b>(1)</b>	The Netherlands	2021
	Inspection and certification services for building owners	<b>(1)</b>	France	2016

Subtotal NAV 15 largest investments (in € mio)





## Twenty largest investments make up 61% of total portfolio value (ctd) > rank 16 to 20

Company	Activity	Platform	Location	Entry
JOOLZ POSITIVE DESIGN	Premium baby strollers	ظ) خ	The Netherlands	2016
FRONNT running your energy transition	One-stop shop for technical installations, products & services	<b>(1)</b>	Belgium	2022
	Digital marketing solutions	ظ)	France	2022
WENAS ABSPERTECHNIK	Road safety equipment	<b>(1)</b>	Germany	2017
LA COMTOISE	Developer and supplier of tailor-made cheese solutions	ظ) خ	France	2018


Subtotal NAV 20 largest investments (in € mio)





## High valuation result is the main driver of the total portfolio increase to € 1.642mio


(in € mio)






### 59 portfolio companies with a value of € 1.64bn

#### Portfolio by platform




#### Portfolio by region






#### Portfolio breakdown according to valuation method and vintage

#### Platform portfolio by valuation method



Weighted average EV/EBITDA-ratio: 8.7x (after 21% negative calibration effect)

#### Platform portfolio by ageing\*





<sup>\*</sup> related to the year of initial investment

### Portfolio with 59 companies and a value of € 1.64bn





#### Disclaimer

- This document is being provided to you solely for your information. It is confidential, is not intended for distribution to the press or other media, and may not be reproduced or redistributed by mail, facsimile, electronic or computer transmission or by any other means to any other person.
- The information contained herein has been prepared using sources believed by Gimv NV ("Gimv") to be reliable. Whilst reasonable care has been taken to ensure that the facts stated herein are accurate and that the opinions and expectations contained herein are fair and reasonable, no representation or warranty, express or implied, is made by Gimv or its affiliates, with respect to the fairness, completeness, correctness, reasonableness or accuracy of any information and opinions contained herein. Any opinion, estimate or projection contained herein constitutes an opinion, estimate or projection as of the date of this document, and there can be no assurance that future results will be consistent with any such opinion, estimate or projection. The information in this presentation is subject to change without notice, it may be incomplete or condensed, and it may not contain all material information concerning Gimv. Without limiting the generality of the foregoing, liability for negligent misstatement in respect of the contents of, or any omission from, this document are hereby expressly excluded.
- Please be aware that the distribution of this document or the information contained in this document or otherwise provided in this meeting may be restricted by law in certain jurisdictions outside Belgium. Gimv does not represent that this information may be lawfully distributed in jurisdictions outside Belgium or that its shares may be lawfully offered in compliance with any applicable registration or other requirements in jurisdictions outside Belgium or pursuant to any exemption available thereunder. Gimv does not assume any responsibility for such distribution or offering. Accordingly, Gimv's shares may not be offered or sold, directly or indirectly, and this information may not be distributed or published outside Belgium, except in circumstances that will result in compliance with any applicable laws and regulations. Persons in whose possession this document or any of the shares come, must inform themselves about, and observe, any such restrictions.
- This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in Gimv nor should it or any part of it nor the fact of, its distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation thereto.
- It is the responsibility of any person not resident in Belgium who wishes to obtain this document or acquire shares of Gimv to ascertain that the legislation applicable in his or her country of residence is complied with and that all other formalities that may be required are fulfilled.
- Special Note With Respect to the United States and US Persons: Gimv's shares have not been and will not be registered under the US Securities Act of 1933 (the "US Securities Act") or qualified for sale under the laws of any state of the United States. In addition, Gimv is not and will not be registered under the US Investment Company Act of 1940. Neither this document nor any copy of it nor the information provided in it may be distributed directly or indirectly in the United States or to US persons (as defined in Regulation S of the US Securities Act). Gimv's shares may not be offered, sold or delivered in the United States of America or to, for the account or benefit of, US persons. Each recipient of this document is deemed to be representing to Gimv that it is not a US person, is not acting on behalf of a US person and will not distribute this document, directly or indirectly, or any copy of it or the information provided herein in the United States or to any US person.



